Evidence map›Paper›PMID 36662360›Full record

ArticleMolecular neurobiology2023

Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines.

Alev Selek, Zehra Seda Unal Halbutoğulları, Çiğdem İnci Aydemir, Berrin Cetinarslan, Zeynep Canturk, Ilhan Tarkun, Gülay Erman, Cansu Subaşı, Karaöz Erdal

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Alev SelekDepartment of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli University, Umuttepe Kocaeli, Turkey. alevselek@gmail.com.ORCID http://orcid.org/0000-0002-0646-8697
Zehra Seda Unal HalbutoğullarıDepartment of Medical Biology, Faculty of Medicine, Center for Stem Cell and Gene Therapies Research and Practice, Kocaeli University, Kocaeli University, Umuttepe Kocaeli, Turkey.
Çiğdem İnci AydemirThe Department of Bioengineering, Bursa Technical University, Bursa, Turkey.
Berrin CetinarslanDepartment of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli University, Umuttepe Kocaeli, Turkey.
Zeynep CanturkDepartment of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli University, Umuttepe Kocaeli, Turkey.
Ilhan TarkunDepartment of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli University, Umuttepe Kocaeli, Turkey.
Gülay ErmanDepartment of Medical Biology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
Cansu SubaşıStembio Stem Cell Tecnologies, Istanbul, Turkey.
Karaöz ErdalCenter for Stem Cell and Tissue Engineering Research & Pracitce, İstinye University, İstanbul, Turkey.
Kocaeli Üniversitesi · TRBursa Technical University · TRIstinye University · TRSakarya University · TR

Funding

Kocaeli Üniversitesi 2013/155
6 · The paper itself

Abstract

Aromatase enzyme plays an essential role in estrogen-induced tumorigenesis. It is expressed in the normal pituitary and more significantly in prolactinoma tissues. The aim of this study was to investigate the effects of an aromatase inhibitor, letrozole, on MMQ and GH3 rat prolactinoma cell lines and evaluate the possible mechanism of action. MMQ and GH3 cells were characterized with demonstrating aromatase enzyme and estrogen receptor alpha expression by PCR and immunofluorescence staining. After dose optimization for testosterone (T) and letrozole (L), four groups were established: only the testosteron-treated group (T) to detect cell proliferation; only letrozole-treated group (L) to investigate apoptotic effects; testosterone and letrozole concomitant-treated group to demonstrate inhibition of testosterone induced cell proliferation with letrozole treatment s(T + L) and control group (C) with no treatment. The proliferation rate of cells was determined by WST-1. For the detection of apoptotic and necrotic cells, Annexin V and caspase-3 labeling was used. Prolactin and estrogen levels were measured with ELISA, and the mRNA expression of aromatase and Esr1 was also determined. Testosterone induced the proliferation of MMQ and GH3 cells and further increased prolactin and estradiol levels. Adding letrozole to testosterone resulted in decreased cellular proliferation and even induced apoptosis. Also, letrozole administration significantly decreased prolactin and estradiol levels. However, letrozole alone had no effects on proliferation and apoptosis. Gene expression of aromatase and Esr1 was also significantly decreased by letrozole treatment. This in vitro study demonstrated that treatment of testosterone proliferating cells with letrozole resulted in decreased prolactin levels and cell proliferation and induced apoptosis, and further loss of aromatase and Esr1 mRNA expression were observed. Although this is an in vivo study, the results showed unique and novel findings which may easily be adapted to clinical use for further verification.

Indexed as

Pituitary NeoplasmsProlactinomaAnimalsApoptosisAromataseCell Line, TumorCell ProliferationEstradiolEstrogensLetrozoleNitrilesProlactinRatsRNA, MessengerTestosteroneAromataseEstradiolEstrogensLetrozoleNitrilesProlactinRNA, MessengerTestosteroneAromataseAromatase inhibitorsEstrogen receptorProlactinProlactinoma

Identifiers

PMID36662360
OpenAlexW4317567087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.